Research programme: PC-DAC:Insulin - ConjuChem

Drug Profile

Research programme: PC-DAC:Insulin - ConjuChem

Alternative Names: CJC-1525; CJC-1525/CJC-1575; CJC-1575; PC-DAC™:Insulin; PC-Insulin

Latest Information Update: 16 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ConjuChem Biotechnologies
  • Developer ConjuChem
  • Class Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 30 Aug 2011 Preclinical development is ongoing in USA
  • 30 Aug 2011 ConjuChem Biotechnologies relaunched as ConjuChem LLC
  • 09 Jun 2009 Pharmacodynamics & pharmacokinetics data from preclinical trials in Diabetes mellitus presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top